Add Formweb to your mobile device
Search results for:
leuprolide
leuprolide
- Hazardous Drugs Handling Guide (Group 1: Antineoplastic)
- Therapeutic Substitutions Leuprolide IM (Lupron) to SQ (Eligard)
- Cell Status NFISA
- * Non-Formulary
Brand names: ELIGARD, Lupron Depot
| Form | Strength | |
|---|---|---|
| POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 3.75 mg/month; 7.5 mg/month; 11.25 mg/3 months; 22.5 mg/3 months; 30 mg/4 months | |
| SUBCUTANEOUS POWDER FOR SUSPENSION | 7.5 mg/month; 22.5 mg/3 months; 30 mg/4 months; 45 mg/6 months |
Last updated: Dec. 19, 2022
Please note that therapeutic substitution protocol exists allowing Eligard for Lupron switch. If specialist or patients persist and concerns arise, please contact pharmacy.
AUGUST 2018 P&T MINUTES
JULY 2017 P&T MINUTES